Webinar - The Future of Life Sciences VC: Examining Specialist vs. Hyper-Targeted Investment Strategies

Want to hear how life sciences VCs are navigating evolving market conditions? On May 8, our Founding partner Farzad lead a debate about the effectiveness of specialist funds versus hyper-targeted approaches, offering valuable perspectives on shaping successful investment strategies.
Leading voices from venture, pharma, and biotech joined Farzad Abdi-Dezfuli for a dynamic discussion. Farzad was joined by Willem van Werperen – Pluvia Biotech, Ester Caffarel-Salvador – Chiesi, Bauke Anninga – M Ventures, Jonathan Gertler – Back Bay Life Science Advisors, Morgan Haller – Forbion.
They explored the trade-offs between specialist and hyper-targeted VC models, real-world examples of drivers, outcome-metrics, and decision logic for fund GPs, LPs, and entrepreneurs. Finally, they touched upon the future direction of life science investing is heading.
“One of the standout moments for me was when the panel challenged the conventional wisdom that capital cycles dictate strategic decisions pointing out that ‘you don’t necessarily get a better ROI or a better multiple’ just because funding is more available. The emphasis on efficient capital deployment over market timing, especially in under-capitalized regions like the Nordics, anchored the discussion in reality. ‘You need to parse out clearly the most efficient way to get there’ was a clear call for focus and discipline, regardless of whether a company is working on a rare disease or a broad-based cardiovascular play.” - adds Farzad.
For more golden nuggets, watch the recording of the webinar here.